SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modula… [+18545 chars]...
Read moreSurrozen, Inc. (NASDAQ:SRZN – Free Report) – Equities researchers at HC Wainwright cut their Q2 2025 earnings estimates for Surrozen in a report released on Monday, May 12th. HC Wainwright analyst M.… [+3770 chars]...
Read moreSurrozen (NASDAQ:SRZN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $32.00 target p… [+3255 chars]...
Read moreGeode Capital Management LLC grew its position in Surrozen, Inc. (NASDAQ:SRZN – Free Report) by 26.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exch… [+2946 chars]...
Read moreNewly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -in… [+9220 chars]...
Read more